Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/17 | $42,500,000 | Series A |
Atlas Venture Lightstone Ventures OrbiMed Advisors | undisclosed |
